Technology Search
Your search returned '164' results
-
Fecal DNA testing for colorectal screening
Agency: AETSA
Name: PreGen-Plus
Technology Type: Diagnostics
Patient Indications: Colorectal cancer (CRC) is the second leading cause of cancer death for men and women, after lung cancer and breast cancer respectively. According to recommendations of the American Cancer Society, everyone aged 50 and over should be screened regularly for colorectal cancer, however less than 40% of that people undergo screening.
Entered On: April 15 2009
-
Stem cells treatment for patients with heart diseases
Agency: AETSA
Name: Stem cells
Technology Type: Procedure
Patient Indications: Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world
Entered On: April 15 2009
-
Hypertonic saline therapy for cystic fibrosis
Agency: ANZHSN
Name: Hypertonic saline therapy for cystic fibrosis
Technology Type: Procedure
Patient Indications: Patients with cystic fibrosis.
Entered On: June 30 2009
-
Victoza – Liraglutide for diabetes mellitus type 2
Agency: DMTP
Name: Victoza – Liraglutide for diabetes mellitus type 2
Technology Type: Drug
Patient Indications: as above
Entered On: November 3 2009
-
Dexamethasone intravitreal implant (Posurdex) for macular oedema
Agency: NHSC
Name: Dexamethasone intravitreal implant
Technology Type: Drug
Patient Indications: • Macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).
Entered On: November 5 2009
-
Rilonacept for Cryopyrin associated periodic syndromes
Agency: NHSC
Name: Rilonacept
Technology Type: Drug
Patient Indications: Cryopyrin associated periodic syndromes (CAPS) in people aged 12 and over with severe symptoms of: • Muckle-Wells Syndrome (MWS). • Familial cold autoinflammatory syndrome (FCAS) also known as familial cold uriticaria (FCU).
Entered On: November 5 2009
-
Eritoran tetrasodium for severe sepsis
Agency: NHSC
Name: Eritoran tetrasodium
Technology Type: Drug
Patient Indications: • Severe sepsis - adjunctive therapy. Severe sepsis is diagnosed when there is sepsis with dysfunction, failing or imminent failure of one or more organs, or the presence of shock with sepsis (1).
Entered On: November 5 2009
-
HandTutor for hand rehabilitation
Agency: NHSC
Name: HandTutor
Technology Type: Drug
Patient Indications: Hand dysfunction due to underlying neurological conditions e.g. cerebral palsy, stroke, multiple sclerosis (MS), traumatic brain injury, movement disorders, nerve injury and post hand surgery.
Entered On: November 5 2009
-
Yttrium 90 microsphere radioembolization
Agency: Osteba
Name: Yttrium 90 microsphere radioembolization
Technology Type: Procedure
Patient Indications: liver cancer
Entered On: November 16 2009
-
Eckart Klobe Suction Cup
Agency: Osteba
Name: Eckart Klobe Suction Cup
Technology Type: Procedure
Patient Indications: Pectus Excavatum patients
Entered On: November 16 2009
-
Hemobye. Treatment for haemorrhoids
Agency: Osteba
Name: Hemobye. Treatment for haemorrhoids
Technology Type: Device
Patient Indications: haemorrhoids
Entered On: November 19 2009
-
Ibritumomab tiuxetan as consolidation therapy after first remission of follicular lymphomas
Agency: LBI -HTA
Name: Ibritumomab tiuxetan, Zevalin
Technology Type: Drug
Patient Indications: Ibritumomab tiuxetan is indicated as consolidation therapy after first remission induction in patients with follicular lymphoma.
Entered On: November 20 2009
-
Checklist from WHO for safe surgery
Agency: NOKC
Name: Surgical safety schecklist
Technology Type: Procedure
Patient Indications: All patients submitted for sugical procedures
Entered On: November 20 2009
-
Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes
Agency: LBI -HTA
Name: Azacitidine, Vidaza®
Technology Type: Drug
Patient Indications: Azacitidine (Vidaza®) is indicated for the treatment of intermediate-2 and high risk MDS (according to International Prognostic Scoring System (IPSS)), chronic myelomonocytic leukemia and acute myeloid leukaemia in adults who are not eligible for haematopoietic stem-cell transplantation.
Entered On: November 20 2009
-
Rituximab for the treatment of chronic lymphocytic leukaemia
Agency: LBI -HTA
Name: Rituximab, Rituxan®, MabThera®
Technology Type: Drug
Patient Indications: Rituximab is indicated for the first-line treatment of patients with chronic lymphocytic leukaemia (CLL) in combination with chemotherapy.
Entered On: November 20 2009
-
Cervista™ HPV 16/18 for the identification of strains of HPV associated with cervical cancer
Agency: ANZHSN
Name: Cervista™ HPV 16/18
Technology Type: Diagnostics
Patient Indications: All sexually active women who return an ambiguous Pap smear.
Entered On: December 1 2009
-
Rapid urine test for Chlamydia trachomatis
Agency: ANZHSN
Name: Chlamydia Rapid Test
Technology Type: Diagnostics
Patient Indications: Sexually active males and females
Entered On: December 1 2009
-
Internet delivered cognitive behavioural therapy for patients with depression
Agency: ANZHSN
Name: Sadness Programme, Fearfighter, Beating the Blues, Anxiety Online
Technology Type: Programme
Patient Indications: For patients suffering from depression
Entered On: December 1 2009
-
Hematopoietic stem cell gene therapy in X-Linked Adrenoleukodystrophy
Agency: HAS
Name: Hematopoietic stem cell gene therapy in X-Linked Adrenoleukodystrophy
Technology Type: Procedure
Patient Indications: Patient with cerebral X-linked adrenoleukodystrophy
Entered On: December 1 2009
-
Wearable artificial kidney (WAK): Portable dialysis for patients with chronic kidney disease
Agency: ANZHSN
Name: Wearable artificial kidney
Technology Type: Device
Patient Indications: Patients with chronic kidney disease (stage 5) or end-stage renal disease (ESRD) usually receive dialysis three times per week in a specialist renal unit. More frequent haemodialysis has been demonstrated to be beneficial to ESRD patients in terms of both survival and quality of life. Benefits for patients include less hypertension, reduced cardiovascular disease, improved patient appetite and nutrition, improved serum albumin levels, improved anaemia and a decrease in the incidence of stroke. All of these factors result in a reduced morbidity and mortality in ESRD patients. Therefore, it has been proposed that a wearable dialysis unit would be of great benefit to ESRD patients (Davenport et al 2007; Gura et al 2005).
Entered On: December 7 2009
-
Recombinant factor XIII (rFXIII) for factor XIII deficiency
Agency: NHSC
Name: Recombinant factor XIII (rFXIII, NN 1841)
Technology Type: Drug
Patient Indications: Congenital factor XIII deficiency.
Entered On: December 15 2009
-
BIBF 1120 for advanced and/or metastatic non-small cell lung cancer – second line
Agency: NHSC
Name: BIBF 1120
Technology Type: Drug
Patient Indications: Non-small cell lung cancer (NSCLC): advanced and/or metastatic stage IIIB/IV or recurrent – second line; in combination with pemetrexed (Alimta) or docetaxel (Taxotere) after failure of prior chemotherapy.
Entered On: December 15 2009
-
Denufosol (denufosol tetrasodium) for cystic fibrosis with mild lung disease
Agency: NHSC
Name: Denufosol (Denufosol tetrasodium, INS37217)
Technology Type: Drug
Patient Indications: Cystic fibrosis with mild lung disease (FEV1 ≥75% of predicted normal).
Entered On: December 15 2009
-
Naproxcinod for osteoarthritis - second line
Agency: NHSC
Name: Naproxcinod
Technology Type: Drug
Patient Indications: Osteoarthritis (OA): adults – second line; after failure of acetaminophen (paracetamol) or non-prescription non-steroidal anti-inflammatory drugs (NSAIDs) to provide symptomatic relief.
Entered On: December 15 2009
-
Tapentadol for severe acute pain
Agency: NHSC
Name: Tapentadol (Palexia)
Technology Type: Drug
Patient Indications: Adults with severe acute pain requiring centrally acting analgesics.
Entered On: December 15 2009